Medication info
Megapregabalin Capsule 75 mg (Pregabalin)

Megapregabalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
L&C Bio Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper half and a white lower half containing white powder that is white or light yellow.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 202001371 · Approved 2020.02.27 · Insurance code 060500390

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, regardless of food. Since this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. Central neuropathic pain — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment: This medicine is eliminated mainly by the kidneys as unchanged drug after entering the systemic circulation. Its clearance is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60 — Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60 — Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30 — Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15 — Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis — Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. No dosage adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years or older): Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children younger than 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
L&C Bio Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunct therapy for partial seizures in epilepsy patients, with or without secondary generalized symptoms. In addition, it helps alleviate symptoms of fibromyalgia. It is widely utilized for various neurological diseases, improving patient symptoms.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, regardless of food. Since this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. Central neuropathic pain — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy — Adults: The initial dose may be 150 mg daily. Based on individual patient response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The initial dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Patients with renal impairment: This medicine is eliminated mainly by the kidneys as unchanged drug after entering the systemic circulation. Its clearance is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60 — Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60 — Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30 — Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15 — Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis — Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to an additional dose administered once. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. No dosage adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years or older): Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children younger than 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if any abnormal changes in mood or behavior occur while taking it, inform your healthcare provider immediately. Do not take this medication if you have an allergy to any of the ingredients or if you have certain genetic lactase deficiency. Diabetic patients should be cautious as weight gain after taking this medication may require adjustments to their blood sugar control medications. If serious allergic reactions such as angioedema occur, stop taking the medication immediately and consult your healthcare provider. Elderly patients should be careful when taking this medication due to an increased risk of falls or injuries caused by dizziness or drowsiness. There may be temporary blurred vision or changes in eyesight; if these symptoms occur, consult your healthcare provider. Sudden discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety; therefore, it should be gradually reduced under medical supervision. Patients with a history of substance abuse should be particularly cautious as there is a higher risk of misuse or dependence with this medication. Patients with severe heart disease or impaired kidney function should consult their healthcare provider prior to taking this medication to determine the appropriate dose adjustment. When taking this medication with opioid analgesics, the risk of central nervous system depression increases, and serious side effects such as breathing difficulties may occur; caution is advised. In early pregnancy, there may be a risk of congenital malformations in the fetus, so it is advisable not to take this medication during pregnancy, and sexually active women should use effective contraception. During breastfeeding, as this medication may be passed into breast milk and affect the baby, consult your healthcare provider about whether to discontinue nursing or the medication. This medication may cause dizziness and drowsiness, so avoid driving or operating hazardous machinery after taking it. In case of overdose, symptoms may include confusion, drowsiness, and seizures; seek emergency treatment immediately. Keep out of reach of children and do not transfer to another container for safety.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal mood and behavior changes, angioedema, facial swelling, periorbital swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, insomnia, depersonalization, paraphilia, restlessness, agitation, mood disorder, emotional lowering, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, speech disorders, myoclonus, decreased reflexes, abnormal movement, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, action tremor, syncope, confusion, hypotonia, olfactory disturbances, ageusia, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, ocular swelling, vision loss, eye pain, eye fatigue, increased tear production, ocular irritation, pupillary dilation, changes in depth perception during vibration, strabismus, brightness of vision, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, bradycardia, paroxysmal tachycardia, paroxysmal arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, decreased oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical spasm, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urine, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, abnormal sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, shock, anaphylactic-like symptoms, mucocutaneous syndrome, erythema multiforme, delirium, paralysis, facial paralysis, affective disorder, agitation, restlessness, worsening of convulsions, drowsiness, state of confusion, depression

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is best kept at room temperature between 15 degrees and 30 degrees Celsius. By storing it this way, the effectiveness of the medication is well maintained and can be used safely.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper half and a white lower half containing white powder that is white or light yellow.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.